Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background and Purpose: The glucagon‐like peptide 1 (GLP‐1) receptor performs an important role in glycaemic control, stimulating the release of insulin. It is an attractive target for treating type 2 diabetes. Recently, several reports of adverse side effects following prolonged use of GLP‐1 receptor therapies have emerged: most likely due to an incomplete understanding of signalling complexities. Experimental Approach: We describe the expression of the GLP‐1 receptor in a panel of modified yeast strains that couple receptor activation to cell growth via single G α/yeast chimeras. This assay enables the study of individual ligand–receptor G protein coupling preferences and the quantification of the effect of GLP‐1 receptor ligands on G protein selectivity. Key Results: The GLP‐1 receptor functionally coupled to the chimeras representing the human G αs, G αi and G αq subunits. Calculation of the dissociation constant for a receptor antagonist, exendin‐3 revealed no significant difference between the two systems. We obtained previously unobserved differences in G protein signalling bias for clinically relevant therapeutic agents, liraglutide and exenatide; the latter displaying significant bias for the G αi pathway. We extended the use of the system to investigate small‐molecule allosteric compounds and the closely related glucagon receptor. Conclusions and Implications: These results provide a better understanding of the molecular events involved in GLP‐1 receptor pleiotropic signalling and establish the yeast platform as a robust tool to screen for more selective, efficacious compounds acting at this important class of receptors in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“GPCR specificity for individual yeast chimeras has previously been demonstrated to generally conform to that observed in mammalian cells, indeed the GLP-1 receptor has been reported to couple through Gαs, Gαi and Gαq in other systems (Baggio and Drucker, 2007).”
BackgroundMethodInfluentialBrown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Self-citationMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
New Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · cited 2×
“The observation that a greater insulin response occurs following oral glucose administration than with an equivalent i.v. challenge leads to the proposal of the incretin effect (McIntyre et al., 1964).”
BackgroundInfluentialSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“3658 British Journal of Pharmacology (2014) 171 3651–3665 and do not exhibit the same affects in clinics (Anderson and Trujillo, 2010; Franks et al., 2012; Singh et al., 2013).”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 1×
“Significantly, however, it is thought that oxyntomodulin, differing from glucagon only through an eight-amino acid C-terminal extension, exerts its affects, in mammalian cells primarily via the GLP-1 receptor, acting to reduce food intake in humans (Wynne et al., 2005; Schepp et al., 1996).”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 4×
“Several orally active, non-peptidyl agonists of the GLP-1 receptor have been described including the substituted quinoxaline, compound 2 (Knudsen et al., 2007) and the pyrimidinebased, BETP (also termed compound B, Sloop et al., 2010).”
BackgroundInfluentialSloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · cited 6×
“These molecules have been shown to bind to the receptor in allosteric sites each having differing agonist affects on GLP-1 receptor-mediated cAMP accumulation (Knudsen et al., 2007; Sloop et al., 2010).”
BackgroundResultInfluential
Cited by
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189
Self-citationAllostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Metadata
- Authors
- Weston, C., Poyner, D., Patel, V, Dowell, S., & Ladds, G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-07-17
- Volume
- 171
- Issue
- 15
- Pages
- 3651-3665
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1933158260
- Cited by
- 53
- References
- 12
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast. https://app.cochat.ai/papers/10.1111/bph.12716
- The paper
- Weston, C., Poyner, D., Patel, V, Dowell, S., & Ladds, G. (2014). Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast. British Journal of Pharmacology. https://doi.org/10.1111/bph.12716
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.